Free Radicals How a Stanford & Google AI pioneer invests in longevity biotech - Karl Pfleger
25 snips
Feb 10, 2026 Karl Pfleger, AI researcher turned longevity philanthropist and angel investor focused on rejuvenation biotech. He discusses why epigenetic reprogramming is powerful but incomplete. He outlines separable molecular pathologies and the need for combinatorial, repeatable rejuvenation therapies. He also explains why better diagnostics could unlock personalized aging interventions.
AI Snips
Chapters
Books
Transcript
Episode notes
Partial Reprogramming Is High-Leverage, Not Magical
- Epigenetic reprogramming rejuvenates cells but does not fix all aging subpathologies like extracellular matrix crosslinks or some toxic metabolites.
- Pfleger calls it promising and high-leverage, but not a single-shot cure for whole-body aging.
Prefer Intermittent Rejuvenation Therapies
- Invest in therapies that produce repeatable, intermittent rejuvenation rather than lifelong daily maintenance.
- Prefer approaches that undo damage faster than it accumulated so they can be dosed infrequently and iterated.
How Karl Chooses Investments
- Karl describes his personal investment filter: he backs therapies that are part of a rejuvenation solution, excluding modest rate-slowers.
- He also funds diagnostics and prefers interventions that are repeatable and intermittent.
